The Lancet. Haematology 2018-01
Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.
Related Questions
New answer by Medical Oncologist at Albert Einstein College of Medicine (July 27, 2018)
My choice of first-line therapy for high-risk MDS patients that are not transplant candidates tends to still be a hypomethylating agent (HMA). I send a myeloid molecular profi...